secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2026-04-10T23:59:59+00:00
Accession:  0001104659-26-041784
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia doses first patient in higher-dose Phase 1 study of DA-1726 for obesity
-------------------------------------------------------------------------------

- Part 3 of Phase 1 evaluates one-step (16→48 mg) and two-step (16→32→64 mg) titration over 16 weeks in 40 obese adults.
- Previously reported ~9% weight loss at 48 mg dose with favorable tolerability; glycemic and liver benefit signals.
- Data from Part 3 expected in Q4 2026; primary endpoints are safety and tolerability.
- DA-1726 is a dual GLP-1/glucagon (OXM) analog; company aims for differentiated efficacy and simpler titration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926041784/0001104659-26-041784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926041784/mtva-20260410x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-041784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer